Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147217053> ?p ?o ?g. }
- W2147217053 endingPage "208" @default.
- W2147217053 startingPage "190" @default.
- W2147217053 abstract "Monoclonal antibodies represent the fastest growing sector of pharmaceutical biotechnology and a number of antibody-based biopharmaceuticals have been approved for cancer treatment. However, in many cases the antibodies used for the treatment of tumors offer only a modest survival benefit to cancer patients.In the present review-article we intend to analyze: i) the curative regimen gemtuzumab ozogamicin (GO) -mediate characterized by the absence of cytotoxic drugs MDR1-Pgp substrates to overcome the mechanism of action of this multidrug transporter, ii) the safety and efficacy of MDR reversing strategy in AML outcome and, iii) chemical and biological MDR modulators playing a dual relevant medical role as a therapeutic and MDR reversing agents but not yet entered in the clinical setting of AML. Since the similar multidrug transporter protein MDR1-Pgp and its down modulation factors may affect safety and efficacy of already generated antibody drug conjugates (ADCs) a comprehensive overview of the most clinically representative immunoconjugates is reported.ADCs represent one of the most promising strategies to enhance the antitumor activity of antibodies. ADCs comprise an antibody (or an antibody fragment) conjugated to a cytotoxic drug via a chemical linker. The therapeutic concept of ADCs is to use an antibody as a vehicle to selectively delivering a cytotoxic drug specifically to a tumor cell, in most cases by means of binding to target cell surface antigen. As a consequence, ADCs have significant potential for enhancing the antitumor activity of naked antibodies and reducing the systemic toxicity of the conjugated drugs." @default.
- W2147217053 created "2016-06-24" @default.
- W2147217053 creator A5029256636 @default.
- W2147217053 date "2013-01-01" @default.
- W2147217053 modified "2023-09-23" @default.
- W2147217053 title "Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML)." @default.
- W2147217053 cites W1508412813 @default.
- W2147217053 cites W1573414954 @default.
- W2147217053 cites W1595188935 @default.
- W2147217053 cites W1601736893 @default.
- W2147217053 cites W1821781403 @default.
- W2147217053 cites W1927327874 @default.
- W2147217053 cites W1958840615 @default.
- W2147217053 cites W1965105845 @default.
- W2147217053 cites W1965410481 @default.
- W2147217053 cites W1965659514 @default.
- W2147217053 cites W1967808511 @default.
- W2147217053 cites W1968159549 @default.
- W2147217053 cites W1972343197 @default.
- W2147217053 cites W1977847184 @default.
- W2147217053 cites W1980786842 @default.
- W2147217053 cites W1983266647 @default.
- W2147217053 cites W1983551635 @default.
- W2147217053 cites W1989874094 @default.
- W2147217053 cites W1990564763 @default.
- W2147217053 cites W1990918503 @default.
- W2147217053 cites W1992633542 @default.
- W2147217053 cites W1996820981 @default.
- W2147217053 cites W1997311128 @default.
- W2147217053 cites W2006434892 @default.
- W2147217053 cites W2007125021 @default.
- W2147217053 cites W2008867089 @default.
- W2147217053 cites W2013194808 @default.
- W2147217053 cites W2017982114 @default.
- W2147217053 cites W2018486897 @default.
- W2147217053 cites W201908734 @default.
- W2147217053 cites W2019490712 @default.
- W2147217053 cites W2025922969 @default.
- W2147217053 cites W2025941747 @default.
- W2147217053 cites W2027544868 @default.
- W2147217053 cites W2029037724 @default.
- W2147217053 cites W2030229638 @default.
- W2147217053 cites W2033857851 @default.
- W2147217053 cites W2034068545 @default.
- W2147217053 cites W2034191965 @default.
- W2147217053 cites W2039223287 @default.
- W2147217053 cites W2043228552 @default.
- W2147217053 cites W2043970203 @default.
- W2147217053 cites W2045938592 @default.
- W2147217053 cites W2047055868 @default.
- W2147217053 cites W2048313558 @default.
- W2147217053 cites W2049146466 @default.
- W2147217053 cites W2050413161 @default.
- W2147217053 cites W2053380672 @default.
- W2147217053 cites W2055314701 @default.
- W2147217053 cites W2055757796 @default.
- W2147217053 cites W2056871730 @default.
- W2147217053 cites W2056926817 @default.
- W2147217053 cites W2064611390 @default.
- W2147217053 cites W2066687597 @default.
- W2147217053 cites W2067282464 @default.
- W2147217053 cites W2070012795 @default.
- W2147217053 cites W2073962885 @default.
- W2147217053 cites W2076480510 @default.
- W2147217053 cites W2078822262 @default.
- W2147217053 cites W2079353503 @default.
- W2147217053 cites W2080526805 @default.
- W2147217053 cites W2083670340 @default.
- W2147217053 cites W2083709832 @default.
- W2147217053 cites W2085436951 @default.
- W2147217053 cites W2085774243 @default.
- W2147217053 cites W2088292832 @default.
- W2147217053 cites W2088855804 @default.
- W2147217053 cites W2091371557 @default.
- W2147217053 cites W2093144236 @default.
- W2147217053 cites W2097735053 @default.
- W2147217053 cites W2102648088 @default.
- W2147217053 cites W2106260849 @default.
- W2147217053 cites W2106742754 @default.
- W2147217053 cites W2118872732 @default.
- W2147217053 cites W2120871937 @default.
- W2147217053 cites W2123489103 @default.
- W2147217053 cites W2124514746 @default.
- W2147217053 cites W2125695832 @default.
- W2147217053 cites W2126855868 @default.
- W2147217053 cites W2127568389 @default.
- W2147217053 cites W2127742735 @default.
- W2147217053 cites W2129357329 @default.
- W2147217053 cites W2129884547 @default.
- W2147217053 cites W2132696375 @default.
- W2147217053 cites W2134461311 @default.
- W2147217053 cites W2146440927 @default.
- W2147217053 cites W2148226936 @default.
- W2147217053 cites W2150648608 @default.
- W2147217053 cites W2153310476 @default.
- W2147217053 cites W2154768755 @default.
- W2147217053 cites W2155039968 @default.
- W2147217053 cites W2158810411 @default.